News Gland Pharma Limited

Equities

GLAND

INE068V01023

Market Closed - NSE India S.E. Other stock markets 05:13:48 03/05/2024 pm IST			5-day change	1st Jan Change
1,686 ^INR	-2.08%		-2.42%	-12.37%

29/04	Gland Pharma Names COO	MT
29/04	Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gland Pharma Names COO	29/04	MT
Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024	29/04	CI
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges	29/04	MT
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	08/04	CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	08/04	MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	06/04	CI
Gland Pharma COO, Chief Technical Officer Step Down	25/03	MT
Gland Pharma Limited Announces Change in Management	25/03	CI
Gland Pharma Names New President of Phixen Subsidiary	27/02	MT
Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy	15/02	MT
Gland Pharma's Consolidated Profit Drops in Fiscal Q3	15/02	MT
Transcript : Gland Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024	14/02
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Indian shares set to open lower as hot US inflation spurs rate worries	14/02	RE
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit	24/11	MT
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	18/11	CI
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug	15/11	MT
Gland Pharma Limited Receives Tentative Approval for Angiotensin II Injection	15/11	CI
Abbott India's Q2 profit climbs on strong sales	09/11	RE
Nomura Upgrades Gland Pharma to Neutral From Reduce, Adjusts Price Target to INR1,570 From INR1,157	08/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gland Pharma Limited

Equities

GLAND

INE068V01023

Summary

Filters